## **FOI Request Response information**

| FOI request reference:     | 2016/318                                |
|----------------------------|---|
| Date request received:     | 09/12/2016                              |
| Date request responded to: | 01/02/2017                              |
| Category:                  | Pharmacy                                |
| Tags:                      | Drugs, anti-TNF, arthritis, cost, spend |

## **Request Detail:**

- 1. What is the Trust's annual spend on anti-TNF drugs (most recent year available)?
- 2. How many patients has the Trust treated with anti-TNF drugs in the last 12 months?
- 3. What is the % split of anti-TNF patients by the following channels:

| Channel    | % of Patients |
|------------|---------------|
| Homecare   |               |
| Outpatient |               |
| Inpatient  |               |

4. How many patients has the Trust treated with the following conditions in last 12 months:

| Condition                 | Number of<br>Patients |
|---------------------------|-----------------------|
| Rheumatoid Arthritis      |                       |
| Crohn's Disease           |                       |
| Psoriasis                 |                       |
| Other anti-TNF Conditions |                       |

5. Are there any gain share agreements in place between the Trust and CCGs for anti-TNF biosimilars?

If yes, please provide:

| Name of CCG | Name of<br>Specific<br>Drug? | Start Date of<br>Agreement | Length of<br>Agreement | Gain Share<br>Split % |
|-------------|------------------------------|----------------------------|------------------------|-----------------------|
|             |                              |                            |                        |                       |
|             |                              |                            |                        |                       |
|             |                              |                            |                        |                       |

## **Response Detail:**

The Trust response to your recent FOI request is as follows:

1. What is the Trust's annual spend on anti-TNF drugs (most recent year available)?

The Trusts annual spend is £0 as all costs are re-charged to the CCG or NHS England.

2. How many patients has the Trust treated with anti-TNF drugs in the last 12 months?
392

3. What is the % split of anti-TNF patients by the following channels:

| Channel    | % of Patients |
|------------|---------------|
| Homecare   | 96.5%         |
| Outpatient | 3.5%          |
| Inpatient  | 0%            |

- 4. We are unable to provide robust information that breaks thisa down further into diagnosis
- 5. Are there any gain share agreements in place between the Trust and CCGs for anti-TNF biosimilars?

No